Condition
Influenza A Subtype H5N1 Infection
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
50%
2 of 4 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
4Total
P 1 (3)
P 4 (1)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT00755703Phase 1CompletedPrimary
Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.
NCT03701061Phase 4CompletedPrimary
Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response
NCT02171819Phase 1CompletedPrimary
Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1
NCT01657929Phase 1CompletedPrimary
H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers
Showing all 4 trials